FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Jensen

Research Profile

Chemicals & Drugs

Anatomy

Tumor Cells, Cultured

Disorders

Co-author Network

Publications

TOP 3
Peter B Jensen; Lars J Jensen; Søren Brunak
Reply to 'Mining electronic health records: an additional perspective'.
Peter B Jensen; Lars J Jensen; Søren Brunak
Mining electronic health records: towards better research applications and clinical care.
Seppo Langer; Maxwell Sehested; Annemette Vinding Thougaard; Peter B Jensen
Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxane.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Jensen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Peter B Jensen; Lars J Jensen; Søren Brunak
Reply to 'Mining electronic health records: an additional perspective'.
Nature reviews. Genetics 2013;14(1):75.
2012: Peter B Jensen; Lars J Jensen; Søren Brunak
Mining electronic health records: towards better research applications and clinical care.
Nature reviews. Genetics 2012;13(6):395-405.
2012: Seppo Langer; Maxwell Sehested; Annemette Vinding Thougaard; Peter B Jensen
Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxane.
Cancer chemotherapy and pharmacology 2012;69(2):573-6.
2010: Uffe Høgh Olesen; Annemette Vinding Thougaard; Peter B Jensen; Maxwell Sehested
A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor.
Molecular cancer therapeutics 2010;9(6):1609-17.
2010: Uffe H Olesen; Jakob G Petersen; Antje Garten; Wieland Kiess; Jun Yoshino; Shin-Ichiro Imai; Mette K Christensen; Peter Fristrup; Annemette Vinding Thougaard; Fredrik Björkling; Peter B Jensen; Søren J Nielsen; Maxwell Sehested
Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.
BMC cancer 2010;10():677.
2009: Lena Marquard; Christian Bjørn Poulsen; Lise Mette Gjerdrum; Peter de Nully Brown; Ib J Christensen; Peter B Jensen; Maxwell Sehested; Preben Johansen; Elisabeth Ralfkiaer
Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas.
Histopathology 2009;54(6):688-98.
2008: L Marquard; L M Gjerdrum; Ib J Christensen; Peter B Jensen; M Sehested; Elisabeth Ralfkiaer
Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma.
Histopathology 2008;53(3):267-77.
2008: M Sorensen; Ulrik Lassen; Peter B Jensen; Kell Østerlind; Nina Jeppesen; Britta Bjerregaard Jensen; Anders Mellemgaard; Carsten Rytter; Seppo Langer
Phase II study of a 3-day schedule with topotecan and cisplatin in patients with previously untreated small cell lung cancer and extensive disease.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(8):902-6.
2008: Lena Marquard; Kamille Dumong Petersen; Morten Persson; Kirsten Damgaard Hoff; Peter B Jensen; Maxwell Sehested
Monitoring the effect of belinostat in solid tumors by H4 acetylation.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2008;116(5):382-92.
2008: M Sorensen; Ulrik Lassen; Torben Palshof; Britta Bjerregaard Jensen; Jørgen Johansen; Peter B Jensen; Seppo Langer
Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trial.
Lung cancer (Amsterdam, Netherlands) 2008;60(2):252-8.
2008: Nagma Khan; Michael Jeffers; Sampath Kumar; Craig Hackett; Ferenc L Boldog; Nicholai Khramtsov; Xiaozhong Qian; Evan Mills; Stanny C Berghs; Nessa Carey; Paul W Finn; Laura S Collins; Anthony Tumber; James W Ritchie; Peter B Jensen; Henri S Lichenstein; Maxwell Sehested
Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
The Biochemical journal 2008;409(2):581-9.
2007: Morten Grauslund; Annemette Vinding Thougaard; Annette Füchtbauer; Kenneth Francis Hofland; Peter Hansen Hjorth; Peter B Jensen; Maxwell Sehested; Ernst-Martin Füchtbauer; Lars H Jensen
A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase IIalpha in vivo.
Molecular pharmacology 2007;72(4):1003-14.
2007: Anthony Tumber; Laura S Collins; Kamille Dumong Petersen; Annemette Vinding Thougaard; Sanne J Christiansen; Marielle Dejligbjerg; Peter B Jensen; Maxwell Sehested; James W A Ritchie
The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo.
Cancer chemotherapy and pharmacology 2007;60(2):275-83.
2007: Henning T Mouridsen; Seppo Langer; J Buter; H Eidtmann; G Rosti; Maike de Wit; P Knoblauch; A Rasmussen; K Dahlstrøm; Peter B Jensen; G Giaccone
Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(3):546-50.
2007: Seppo Langer; Peter B Jensen; Maxwell Sehested
Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries.
Cardiovascular toxicology 2007;7(2):151-3.
2006: Seppo Langer; Annemette Vinding Thougaard; Maxwell Sehested; Peter B Jensen
Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone.
Cancer chemotherapy and pharmacology 2006;57(1):125-8.
2005: Kenneth Francis Hofland; Annemette Vinding Thougaard; Marielle Dejligbjerg; Lars H Jensen; Paul E.G. Kristjansen; Pia Rengtved; Maxwell Sehested; Peter B Jensen
Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(18):6722-9.
2005: Tina K Sorensen; Morten Grauslund; Peter B Jensen; Maxwell Sehested; Lars H Jensen
Separation of bisdioxopiperazine- and vanadate resistance in topoisomerase II.
Biochemical and biophysical research communications 2005;334(3):853-60.
2005: Lars H Jensen; Annemette Vinding Thougaard; Morten Grauslund; Birgitte Søkilde; Elisabeth V Carstensen; Henrik K Dvinge; Dominic A Scudiero; Peter B Jensen; Robert H Shoemaker; Maxwell Sehested
Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors.
Cancer research 2005;65(16):7470-7.
2005: Kenneth Francis Hofland; Annemette Vinding Thougaard; Maxwell Sehested; Peter B Jensen
Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(10):3915-24.
2005: Ulrik Lademann; Maria Unni Rømer; Peter B Jensen; Kenneth Francis Hofland; Lise Larsen; Ib Jarle Christensen; Nils Brünner
Malignant transformation of wild-type but not plasminogen activator inhibitor-1 gene-deficient fibroblasts decreases cellular sensitivity to chemotherapy-mediated apoptosis.
European journal of cancer (Oxford, England : 1990) 2005;41(7):1095-100.
2005: Jerrylaine Vaughn; Shengli Huang; Irene Wessel; Tina K Sorensen; Tao Hsieh; Lars H Jensen; Peter B Jensen; Maxwell Sehested; John L. Nitiss
Stability of the topoisomerase II closed clamp conformation may influence DNA-stimulated ATP hydrolysis.
The Journal of biological chemistry 2005;280(12):11920-9.
2004: Lars H Jensen; Marielle Dejligbjerg; Lasse Tengbjerg Hansen; Morten Grauslund; Peter B Jensen; Maxwell Sehested
Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
BMC pharmacology 2004;4():31.
2004: Jerrylaine V Walker; Karin C Nitiss; Lars H Jensen; Christopher Mayne; Tao Hu; Peter B Jensen; Maxwell Sehested; Tao Hsieh; John L. Nitiss
A mutation in human topoisomerase II alpha whose expression is lethal in DNA repair-deficient yeast cells.
The Journal of biological chemistry 2004;279(25):25947-54.
2004: Patricia E Schroeder; Kenneth Francis Hofland; Peter B Jensen; Maxwell Sehested; Seppo Langer; Brian B Hasinoff
Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent.
Cancer chemotherapy and pharmacology 2004;53(1):91-3.
2003: Axelle Renodon-Cornière; Lars H Jensen; John L. Nitiss; Peter B Jensen; Maxwell Sehested
Analysis of bisdioxopiperazine dexrazoxane binding to human DNA topoisomerase II alpha: decreased binding as a mechanism of drug resistance.
Biochemistry 2003;42(32):9749-54.
2003: Lars H Jensen; Axelle Renodon-Cornière; Karin C Nitiss; Bridget T Hill; John L. Nitiss; Peter B Jensen; Maxwell Sehested
A dual mechanism of action of the anticancer agent F 11782 on human topoisomerase II alpha.
Biochemical pharmacology 2003;66(4):623-31.
2003: Patricia E Schroeder; Peter B Jensen; Maxwell Sehested; Kenneth Francis Hofland; Seppo Langer; Brian B Hasinoff
Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide.
Cancer chemotherapy and pharmacology 2003;52(2):167-74.
2003: Axelle Renodon-Cornière; Tina K Sørensen; Peter B Jensen; John L. Nitiss; Birgitte Søkilde; Maxwell Sehested; Lars H Jensen
Probing the role of linker substituents in bisdioxopiperazine analogs for activity against wild-type and mutant human topoisomerase II alpha.
Molecular pharmacology 2003;63(5):1159-68.
2002: Axelle Renodon-Cornière; Lars H Jensen; John L. Nitiss; Peter B Jensen; Maxwell Sehested
Interaction of human DNA topoisomerase II alpha with DNA: quantification by surface plasmon resonance.
Biochemistry 2002;41(45):13395-402.
2002: Irene Wessel; Lars H Jensen; Axelle Renodon-Corniere; Tina K Sorensen; John L. Nitiss; Peter B Jensen; Maxwell Sehested
Human small cell lung cancer NYH cells resistant to the bisdioxopiperazine ICRF-187 exhibit a functional dominant Tyr165Ser mutation in the Walker A ATP binding site of topoisomerase II alpha.
FEBS letters 2002;520(1-3):161-6.
2002: Lars H Jensen; Axelle Renodon-Corniere; Irene Wessel; Seppo Langer; Birgitte Søkilde; Elisabeth V Carstensen; Maxwell Sehested; Peter B Jensen
Maleimide is a potent inhibitor of topoisomerase II in vitro and in vivo: a new mode of catalytic inhibition.
Molecular pharmacology 2002;61(5):1235-43.
2001: L Rothenborg-Jensen; H F Hansen; Irene Wessel; John L. Nitiss; G Schmidt; Peter B Jensen; Maxwell Sehested; Lars H Jensen
Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
Anti-cancer drug design 2001;16(6):305-15.
2001: Seppo Langer; Maxwell Sehested; Peter B Jensen
Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(3):405-10.
2000: Lars H Jensen; Irene Wessel; M Møller; John L. Nitiss; Maxwell Sehested; Peter B Jensen
N-terminal and core-domain random mutations in human topoisomerase II alpha conferring bisdioxopiperazine resistance.
FEBS letters 2000;480(2-3):201-7.
2000: Seppo Langer; Maxwell Sehested; Peter B Jensen
Treatment of anthracycline extravasation with dexrazoxane.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(9):3680-6.
2000: Seppo Langer; Maxwell Sehested; Peter B Jensen; J Buter; G Giaccone
Dexrazoxane in anthracycline extravasation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(16):3064.
2000: M Sorensen; Peter B Jensen; Jørn Herrstedt; Fred R Hirsch; Heine H Hansen
A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(7):829-35.
2000: Kenneth Francis Hofland; B O Petersen; J Falck; K Helin; Peter B Jensen; Maxwell Sehested
Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1488-97.
2000: Lars H Jensen; Karin C Nitiss; A Rose; J Dong; J Zhou; T Hu; Neil Osheroff; Peter B Jensen; Maxwell Sehested; John L. Nitiss
A novel mechanism of cell killing by anti-topoisomerase II bisdioxopiperazines.
The Journal of biological chemistry 2000;275(3):2137-46.
1999: Peter B Jensen; Maxwell Sehested; Seppo Langer; H H Hansen
Twenty-five years of chemotherapy in small cell lung cancer sends us back to the laboratory.
Cancer treatment reviews 1999;25(6):377-86.
1999: Seppo Langer; G Schmidt; M Sørensen; Maxwell Sehested; Peter B Jensen
Inhibitors of topoisomerase II as pH-dependent modulators of etoposide-mediated cytotoxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10):2899-907.
1999: Irene Wessel; Lars H Jensen; Peter B Jensen; J Falck; A Rose; M Roerth; John L. Nitiss; Maxwell Sehested
Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Cancer research 1999;59(14):3442-50.
1999: J Falck; Peter B Jensen; Maxwell Sehested
Evidence for repressional role of an inverted CCAAT box in cell cycle-dependent transcription of the human DNA topoisomerase IIalpha gene.
The Journal of biological chemistry 1999;274(26):18753-8.
1999: M Sorensen; Maxwell Sehested; Peter B Jensen
Effect of cellular ATP depletion on topoisomerase II poisons. Abrogation Of cleavable-complex formation by etoposide but not by amsacrine.
Molecular pharmacology 1999;55(3):424-31.
1998: M Sorensen; Maxwell Sehested; Ib Jarle Christensen; J K Larsen; Peter B Jensen
Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation.
British journal of cancer 1998;77(12):2152-61.
1998: B Holm; Maxwell Sehested; Peter B Jensen
Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(6):1367-73.
1998: J Kreisholt; M Sorensen; Peter B Jensen; Boye Nielsen; C B Andersen; Maxwell Sehested
Immunohistochemical detection of DNA topoisomerase IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer.
British journal of cancer 1998;77(9):1469-73.
1998: Maxwell Sehested; Irene Wessel; Lars H Jensen; B Holm; R S Oliveri; S Kenwrick; A M Creighton; John L. Nitiss; Peter B Jensen
Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Cancer research 1998;58(7):1460-8.
1997: Irene Wessel; Peter B Jensen; J Falck; S E Mirski; SUSAN COLE; Maxwell Sehested
Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase IIalpha in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization.
Cancer research 1997;57(20):4451-4.
1997: Peter B Jensen; Maxwell Sehested
DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide.
Biochemical pharmacology 1997;54(7):755-9.
1997: M Sorensen; Maxwell Sehested; Peter B Jensen
pH-dependent regulation of camptothecin-induced cytotoxicity and cleavable complex formation by the antimalarial agent chloroquine.
Biochemical pharmacology 1997;54(3):373-80.
1997: Peter B Jensen; B Holm; M Sorensen; Ib Jarle Christensen; Maxwell Sehested
In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.
British journal of cancer 1997;75(6):869-77.
1996: Maxwell Sehested; Peter B Jensen
Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle.
Biochemical pharmacology 1996;51(7):879-86.
1996: B Holm; Peter B Jensen; Maxwell Sehested
ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
Cancer chemotherapy and pharmacology 1996;38(3):203-9.
1995: M Sorensen; Maxwell Sehested; Peter B Jensen
Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
British journal of cancer 1995;72(2):399-404.
1995: I Brock; DR Hipfner; Boye Nielsen; Peter B Jensen; Roger G Deeley; SUSAN COLE; Maxwell Sehested
Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells.
Cancer research 1995;55(3):459-62.
1995: Peter B Jensen; Maxwell Sehested
In vitro models for testing of cytostatic agents in small cell lung cancer.
Cancer treatment and research 1995;72():171-91.
1994: Peter B Jensen
Differential sensitivity patterns in small cell lung cancer cell lines: detection and circumvention of resistance to topoisomerase II targeting drugs.
Danish medical bulletin 1994;41(5):475-88.
1994: Peter B Jensen; B S Sørensen; Maxwell Sehested; P Grue; Erland J F Demant; Heine H Hansen
Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments.
Cancer research 1994;54(11):2959-63.
1994: B S Sørensen; Peter B Jensen; Maxwell Sehested; P S Jensen; E Kjeldsen; O F Nielsen; J Alsner
Antagonistic effect of aclarubicin on camptothecin induced cytotoxicity: role of topoisomerase I.
Biochemical pharmacology 1994;47(11):2105-10.
1994: B Holm; Peter B Jensen; Maxwell Sehested; Heine H Hansen
In vivo inhibition of etoposide-mediated apoptosis, toxicity, and antitumor effect by the topoisomerase II-uncoupling anthracycline aclarubicin.
Cancer chemotherapy and pharmacology 1994;34(6):503-8.
1994: L N Petersen; Peter B Jensen; B S Sørensen; Svend A Engelholm; Mogens Spang-Thomsen
Postincubation with aclarubicin reverses topoisomerase II mediated DNA cleavage, strand breaks, and cytotoxicity induced by VP-16.
Investigational new drugs 1994;12(4):289-97.
1993: Maxwell Sehested; Peter B Jensen; B S Sørensen; B Holm; Ellen Friche; Erland J F Demant
Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16).
Biochemical pharmacology 1993;46(3):389-93.
1993: Peter B Jensen; B S Sørensen; Maxwell Sehested; Erland J F Demant; E Kjeldsen; Ellen Friche; Heine H Hansen
Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance.
Biochemical pharmacology 1993;45(10):2025-35.
1993: Peter B Jensen; Ib Jarle Christensen; Maxwell Sehested; Heine H Hansen; Lars L Vindeløv
Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines.
British journal of cancer 1993;67(2):311-20.
1992: B S Sørensen; J Sinding; Anni H Andersen; J Alsner; Peter B Jensen; Ole Westergaard
Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events.
Journal of molecular biology 1992;228(3):778-86.
1992: Maxwell Sehested; Ellen Friche; Peter B Jensen; Erland J F Demant
Relationship of VP-16 to the classical multidrug resistance phenotype.
Cancer research 1992;52(10):2874-9.
1992: Ellen Friche; Peter B Jensen; NI Nissen
Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor.
Cancer chemotherapy and pharmacology 1992;30(3):235-7.
1992: Peter B Jensen; H Roed; Maxwell Sehested; Erland J F Demant; Lars L Vindeløv; Ib Jarle Christensen; Heine H Hansen
Doxorubicin sensitivity pattern in a panel of small-cell lung-cancer cell lines: correlation to etoposide and vincristine sensitivity and inverse correlation to carmustine sensitivity.
Cancer chemotherapy and pharmacology 1992;31(1):46-52.
1992: Peter B Jensen; S K Larsen; I Stilbo
Phase II study of high-dose aclarubicin in previously treated patients with small-cell lung cancer.
Cancer chemotherapy and pharmacology 1992;30(3):219-20.
1991: Erland J F Demant; Peter B Jensen; Maxwell Sehested
Characterization of the cooperative cross-linking of doxorubicin N-hydroxysuccinimide ester derivatives to water soluble proteins.
Biochimica et biophysica acta 1991;1118(1):83-90.
1991: Peter B Jensen; P S Jensen; Erland J F Demant; Ellen Friche; B S Sørensen; Maxwell Sehested; K Wassermann; Lars L Vindeløv; Ole Westergaard; Heine H Hansen
Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II.
Cancer research 1991;51(19):5093-9.
1991: P Bouchelouche; Ellen Friche; Maxwell Sehested; Peter B Jensen; T Skovsgaard
Cytosolic free Ca2+ in daunorubicin and vincristine resistant Ehrlich ascites tumor cells. Drug accumulation is independent of intracellular Ca2+ changes.
Biochemical pharmacology 1991;41(2):243-53.
1990: Erland J F Demant; Maxwell Sehested; Peter B Jensen
A model for computer simulation of P-glycoprotein and transmembrane delta pH-mediated anthracycline transport in multidrug-resistant tumor cells.
Biochimica et biophysica acta 1990;1055(2):117-25.
1990: Maxwell Sehested; T Skovsgaard; Peter B Jensen; Erland J F Demant; Ellen Friche; N Bindslev
Transport of the multidrug resistance modulators verapamil and azidopine in wild type and daunorubicin resistant Ehrlich ascites tumour cells.
British journal of cancer 1990;62(1):37-41.
1990: Ellen Friche; Peter B Jensen; H Roed; T Skovsgaard; NI Nissen
In vitro circumvention of anthracycline--resistance in Ehrlich ascites tumour by anthracycline analogues.
Biochemical pharmacology 1990;39(11):1721-6.
1990: Peter B Jensen; B S Sørensen; Erland J F Demant; Maxwell Sehested; P S Jensen; Lars L Vindeløv; Heine H Hansen
Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.
Cancer research 1990;50(11):3311-6.
1990: Peter B Jensen; H Roed; T Skovsgaard; Ellen Friche; Lars L Vindeløv; Heine H Hansen; Mogens Spang-Thomsen
Antitumor activity of the two epipodophyllotoxin derivatives VP-16 and VM-26 in preclinical systems: a comparison of in vitro and in vivo drug evaluation.
Cancer chemotherapy and pharmacology 1990;27(3):194-8.
1990: Ellen Friche; Peter B Jensen; Maxwell Sehested; Erland J F Demant; N N Nissen
The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor.
Cancer communications 1990;2(9):297-303.
1989: Maxwell Sehested; Peter B Jensen; T Skovsgaard; N Bindslev; Erland J F Demant; Ellen Friche; Lars L Vindeløv
Inhibition of vincristine binding to plasma membrane vesicles from daunorubicin-resistant Ehrlich ascites cells by multidrug resistance modulators.
British journal of cancer 1989;60(6):809-14.
1989: Peter B Jensen; Lars L Vindeløv; H Roed; Erland J F Demant; Maxwell Sehested; T Skovsgaard; Heine H Hansen
In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL).
British journal of cancer 1989;60(6):838-44.
1989: Peter B Jensen; H Roed; Lars L Vindeløv; Ib Jarle Christensen; Heine H Hansen
Reduced variation in the clonogenic assay obtained by standardization of the cell culture conditions prior to drug testing on human small cell lung cancer cell lines.
Investigational new drugs 1989;7(4):307-15.
1989: Maxwell Sehested; N Bindslev; Erland J F Demant; T Skovsgaard; Peter B Jensen
Daunorubicin and vincristine binding to plasma membrane vesicles from daunorubicin-resistant and wild type Ehrlich ascites tumor cells.
Biochemical pharmacology 1989;38(18):3017-27.
1989: P Afzelius; Erland J F Demant; Gert H Hansen; Peter B Jensen
Covalent modification of serum transferrin with phospholipid and incorporation into liposomal membranes.
Biochimica et biophysica acta 1989;979(2):231-8.